Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells

Summary Methylation of lysine residues on histone tail is a dynamic epigenetic modification that plays a key role in chromatin structure and gene regulation. Members of the KDM5 (also known as JARID1) sub-family are 2-oxoglutarate (2-OG) and Fe2+-dependent oxygenases acting as histone 3 lysine 4 trimethyl (H3K4me3) demethylases, regulating proliferation, stem cell self-renewal, and differentiation. Here we present the characterization of KDOAM-25, an inhibitor of KDM5 enzymes. KDOAM-25 shows biochemical half maximal inhibitory concentration values of <100 nM for KDM5A-D in vitro, high selectivity toward other 2-OG oxygenases sub-families, and no off-target activity on a panel of 55 receptors and enzymes. In human cell assay systems, KDOAM-25 has a half maximal effective concentration of ∼50 μM and good selectivity toward other demethylases. KDM5B is overexpressed in multiple myeloma and negatively correlated with the overall survival. Multiple myeloma MM1S cells treated with KDOAM-25 show increased global H3K4 methylation at transcriptional start sites and impaired proliferation.

[1]  A. Gingras,et al.  Incorporating DNA shearing in standard affinity purification allows simultaneous identification of both soluble and chromatin-bound interaction partners. , 2014, Journal of proteomics.

[2]  Margaret A. Johns,et al.  Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds. , 2016, Cell chemical biology.

[3]  Alexander Roesch,et al.  A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth , 2010, Cell.

[4]  R. Poulsom,et al.  PLU-1, a transcriptional repressor and putative testis-cancer antigen, has a specific expression and localisation pattern during meiosis , 2003, Chromosoma.

[5]  F. von Delft,et al.  Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor† , 2014, MedChemComm.

[6]  Hsien-Da Huang,et al.  Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis. , 2013, Cancer research.

[7]  Akane Kawamura,et al.  Recent Progress in Histone Demethylase Inhibitors. , 2016, Journal of medicinal chemistry.

[8]  Stephen H. Hughes,et al.  H3K4me3 Interactions with TAF3 Regulate Preinitiation Complex Assembly and Selective Gene Activation , 2013, Cell.

[9]  Marcel H. Schulz,et al.  Fiona: a parallel and automatic strategy for read error correction , 2014, Bioinform..

[10]  Christopher J. Schofield,et al.  A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response , 2012, Nature.

[11]  R. Klose,et al.  Dynamic protein methylation in chromatin biology , 2008, Cellular and Molecular Life Sciences.

[12]  J. Taylor‐Papadimitriou,et al.  PLU‐1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: A new cancer/testis antigen? , 2002, International journal of cancer.

[13]  M. Ribeiro,et al.  A novel nonsense mutation in KDM5C/JARID1C gene causing intellectual disability, short stature and speech delay , 2011, Neuroscience Letters.

[14]  K. Helin,et al.  Inhibitors of histone demethylases. , 2011, Bioorganic & medicinal chemistry.

[15]  A. Schnerch,et al.  The Histone Demethylase KDM5b/JARID1b Plays a Role in Cell Fate Decisions by Blocking Terminal Differentiation , 2008, Molecular and Cellular Biology.

[16]  U. Oppermann,et al.  The roles of Jumonji-type oxygenases in human disease , 2014, Epigenomics.

[17]  Dinshaw J. Patel,et al.  Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger , 2009, Nature.

[18]  Chunbo He,et al.  Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer , 2015, Tumor Biology.

[19]  Yukihiro Itoh,et al.  Identification of Jumonji AT-Rich Interactive Domain 1A Inhibitors and Their Effect on Cancer Cells. , 2015, ACS medicinal chemistry letters.

[20]  D. Maloney,et al.  A Cell-Permeable Ester Derivative of the JmjC Histone Demethylase Inhibitor IOX1 , 2014, ChemMedChem.

[21]  A. Ritzén,et al.  Endogenous 2-oxoglutarate levels impact potencies of competitive HIF prolyl hydroxylase inhibitors. , 2011, Pharmacological research.

[22]  Jun Liang,et al.  Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies. , 2016, Bioorganic & medicinal chemistry letters.

[23]  Data production leads,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .

[24]  R. Prinjha,et al.  Structural analysis of human KDM5B guides histone demethylase inhibitor development. , 2016, Nature chemical biology.

[25]  David A. Orlando,et al.  Quantitative ChIP-Seq normalization reveals global modulation of the epigenome. , 2014, Cell reports.

[26]  Jiping Zeng,et al.  Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis , 2014, Molecular Cancer.

[27]  P. Trojer,et al.  An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. , 2016, Nature chemical biology.

[28]  J. Tanny.  Chromatin modification by the RNA Polymerase II elongation complex , 2014, Transcription.

[29]  M. Björkholm,et al.  The histone demethylase RBP2 Is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells. , 2010, Gastroenterology.

[30]  R. Klose,et al.  5-Carboxy-8-hydroxyquinoline is a Broad Spectrum 2-Oxoglutarate Oxygenase Inhibitor which Causes Iron Translocation. , 2013, Chemical science.

[31]  J. Krosl,et al.  RNAi screen identifies Jarid1b as a major regulator of mouse HSC activity. , 2013, Blood.

[32]  K. Helin,et al.  Coordinated regulation of transcriptional repression by the RBP2 H3K4 demethylase and Polycomb-Repressive Complex 2. , 2008, Genes & development.

[33]  Takayoshi Suzuki,et al.  Discovery of KDM5A inhibitors: Homology modeling, virtual screening and structure-activity relationship analysis. , 2016, Bioorganic & medicinal chemistry letters.

[34]  Takahiro Matsumoto,et al.  Spermatogenesis‐specific association of SMCY and MSH5 , 2008, Genes to cells : devoted to molecular & cellular mechanisms.

[35]  ENCODEConsortium,et al.  An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.

[36]  David M. Wilson,et al.  Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives. , 2016, Journal of medicinal chemistry.

[37]  Jiping Zeng,et al.  Histone Demethylase Retinoblastoma Binding Protein 2 is Overexpressed in Hepatocellular Carcinoma and Negatively Regulated by hsa-miR-212 , 2013, PloS one.

[38]  Ratna Chakrabarti,et al.  MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance , 2014, Molecular Cancer.

[39]  Sergey I. Nikolenko,et al.  SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing , 2012, J. Comput. Biol..

[40]  P. Trojer,et al.  Identification of potent, selective KDM5 inhibitors. , 2016, Bioorganic & medicinal chemistry letters.

[41]  S. Peña-Llopis,et al.  A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth , 2013, Nature Communications.

[42]  Douglas W. Thomson,et al.  Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives. , 2016, Journal of medicinal chemistry.

[43]  Kristian Helin,et al.  Molecular mechanisms and potential functions of histone demethylases , 2012, Nature Reviews Molecular Cell Biology.

[44]  G. F. Ruda,et al.  8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors , 2016, Journal of medicinal chemistry.

[45]  J. Choi,et al.  Regulation of the Boundaries of Accessible Chromatin , 2013, PLoS genetics.